- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT03502434
Badanie RIPT (ang. Repeat Insult Patch Test) oceniające potencjał uczulający miejscowego roztworu SM04755 u zdrowych ochotników
Jednoośrodkowe badanie fazy 1 z powtarzalnym testem plastra zniewagi (RIPT) oceniające potencjał uczulający roztworu SM04755 do stosowania miejscowego
This is a single center, randomized, controlled, within subject comparison, single dose study to determine the sensitization potential of SM04755 solution on normal skin under semi-occlusive patch conditions.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
This Phase 1, Repeat Insult Patch Test (RIPT) study is a single-center study of topical SM04755 solution repetitively applied to skin of healthy volunteers. This study will assess the potential of the Test Materials to induce contact sensitization as measured by treatment emergent adverse events (TEAEs), Reaction Grade and Investigator assessment of irritation and sensitization.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 1
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Virginia
-
Lynchburg, Virginia, Stany Zjednoczone, 24503
- Research Site
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Healthy adult males and females at least 18 years of age
- Subjects of any Fitzpatrick skin type or race provided their degree of skin pigmentation does not, in the Investigator or designee's opinion, interfere with study assessments
- Subject has no signs of irritation (i.e., a Reaction Grade of "0") at patch application sites on the back prior to the initial patch application on Day 1
- Subject must have read, understood, and signed the informed consent form prior to any study-related procedure being performed
- Subject is willing and able to comply with all scheduled study visits, urine pregnancy tests (if applicable), contraception requirements (male and female), and other study requirements
- Subject is willing to avoid extensive sun exposure, phototherapy, or use of a tanning salon for the duration of the study
Exclusion Criteria:
- Women who are pregnant or lactating
- Women of childbearing potential who are sexually active and are not willing to use a highly effective method of birth control during the study period that includes double barrier, IUD, or hormonal contraceptive combined with single barrier, or abstinence
- Women of childbearing potential who have had unprotected sexual intercourse within 30 days prior to Day 1
- Males who are sexually active and not willing to use a condom, and have a partner who is capable of becoming pregnant, if neither has had surgery to become sterilized, and/or who are not willing to use double barrier or whose partner is not using a highly effective method of birth control (e.g., IUD, or hormonal contraception combined with single barrier)
- Subject has any skin condition that, in the Investigator's opinion, could interfere with the study assessments or put the subject at undue risk by study participation
- Subject has severe atopic dermatitis/eczema, psoriasis or chronic asthma
- Subject has tattoos, excessive hair, moles, scarring, etc. which would interfere with patching
- Subject has a history of sensitivity to any component of any of the Test Materials
- Use of any of the following medications:
- Systemic or topical glucocorticoids within 4 weeks prior to Day 1
- Systemic or topical analgesics (e.g., NSAIDs, high dose aspirin, etc.) within 1 week prior to Day 1. Note: Daily use of ≤325 mg of aspirin for cardiovascular disease or prophylaxis is allowed. Maximum daily use of Tylenol ≤3000 mg is allowed.
- Antihistamines within 1 week prior to Day 1. Note: H2 blockers such as Pepcid, Zantac, and Tagamet are permitted.
- Anti-inflammatories within 1 week prior to Day 1
- Immunosuppressant medications (e.g., TNF-alpha inhibitors, topical tacrolimus, etc.) within 4 weeks prior to Day 1 (or within 6 half-lives prior to Day 1 for biologics)
- Subject has had previous treatment with SM04755
- Subject has an active infection of hepatitis B or C or human immunodeficiency virus (HIV) infection as determined by an interview
- Participation in a clinical research trial that included the receipt of an investigational product or any experimental therapeutic procedure within 8 weeks prior to Screening, or planned participation in any such trial; the last date of participation in the trial, not the last date of receipt of investigational product, must be at least 8 weeks prior to Screening
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Podwójnie
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: 90 mg/mL SM04755 in water
90 mg/mL SM04755 in water applied via patches |
Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading. |
|
Eksperymentalny: 90 mg/mL SM04755 in aqueous Vehicle
90 mg/mL SM04755 in aqueous Vehicle applied via patches |
Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading. |
|
Eksperymentalny: 90 mg/mL SM04755 in aqueous Vehicle (without Benzyl Alcohol)
90 mg/mL SM04755 in aqueous Vehicle (without Benzyl Alcohol) applied via patches |
Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading. |
|
Inny: Vehicle
Aqueous Vehicle applied via patches |
Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading. |
|
Inny: White petrolatum
White petrolatum (Negative control) applied via patches |
Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading. |
|
Inny: Sodium lauryl sulfate
Sodium lauryl sulfate (SLS 0.5%) (Positive control) applied via patches |
Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Potencjał uczulenia kontaktowego badanego materiału mierzony metodą leczenia
Ramy czasowe: Wartość wyjściowa do dnia 40 (lub przez okres obserwacji w przypadku TEAE)
|
Wartość wyjściowa do dnia 40 (lub przez okres obserwacji w przypadku TEAE)
|
|
|
Potencjał uczulenia kontaktowego badanego materiału mierzony na podstawie oceny podrażnienia i uczulenia przez badacza
Ramy czasowe: Linia bazowa do dnia 40
|
Linia bazowa do dnia 40
|
|
|
Contact sensitization potential of Test Material as measured by Reaction Grade
Ramy czasowe: Baseline to Day 38-40
|
Reaction Grade is measured on a 5-point scale from zero to four (zero = no sign of irritation and 4 = Erythema with edema and blistering) |
Baseline to Day 38-40
|
Współpracownicy i badacze
Sponsor
Śledczy
- Dyrektor Studium: Yusuf Yazici, M.D., Biosplice Therapeutics, Inc.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- SM04755-TOP-02
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .